Home Ingredients UC-II® (Undenatured Type II Collagen — Lonza)
Joint Health

UC-II® (Undenatured Type II Collagen — Lonza)

Evidence Level
Strong
4 Clinical Trials
7 Documented Benefits
4/5 Evidence Score

UC-II® is the patented branded form of undenatured Type II collagen developed by InterHealth Nutraceuticals (now Lonza). It's the form used in essentially all published clinical trials of undenatured Type II collagen for joint health — meaning the entire evidence base for this supplement category is built on UC-II® specifically rather than generic alternatives. The patented low-temperature manufacturing process is what preserves the triple-helix native structure necessary for the oral tolerance mechanism. Standardized to ≥25% native Type II collagen content from chicken sternum, UC-II® at 40 mg/day shows significant osteoarthritis pain reduction over 90-180 days, with a landmark trial demonstrating roughly 2x better WOMAC improvement than glucosamine + chondroitin combination. The honest framing: UC-II® is the form the research validates, and the patented manufacturing matters for this specific supplement class — generic 'undenatured Type II collagen' products carry meaningful uncertainty about whether their processing preserves the active structure. For native Type II collagen specifically, the brand premium has stronger justification than for most supplements.

Studied Dose Clinical trial dose: 40 mg UC-II® once daily (providing ~10 mg native Type II collagen). Take on empty stomach (first thing in morning, 1 hour before food). Effects appear over 30-90 days. Avoid in chicken/egg allergies.
Active Compound UC-II® patented undenatured (native) Type II collagen from chicken sternum (Lonza/InterHealth). Standardized to ≥25% native Type II collagen via patented low-temperature process that preserves triple-helix structure.

Benefits

Knee osteoarthritis pain (patented evidence base)

Multiple randomized trials using UC-II® specifically show 40 mg/day produces 30-40% WOMAC pain reduction in knee osteoarthritis over 90-180 days. The entire published evidence base for undenatured Type II collagen is built on UC-II® — distinguishing it meaningfully from generic alternatives where processing quality is unverified.

Supported by Trial 1, Trial 4

2x better than glucosamine + chondroitin

A 90-day head-to-head trial in 52 OA patients showed UC-II® 40 mg/day reduced WOMAC scores 33% vs 14% for glucosamine 1,500 mg + chondroitin 1,200 mg. VAS pain reduced 40% vs 15.4%. The strongest head-to-head evidence for any joint supplement category — UC-II® is the only joint supplement with this caliber of comparative evidence.

Supported by Trial 1

Multicenter validation trial

A subsequent 191-patient multicenter trial confirmed UC-II® 40 mg/day improved WOMAC scores significantly more than glucosamine + chondroitin over 180 days. Replicates the 2009 trial findings at larger sample size with longer duration — strengthens confidence in the head-to-head superiority claim.

Supported by Trial 2, Trial 1

Exercise-induced knee pain in healthy adults

A trial in 55 healthy active adults with exercise-induced knee pain showed UC-II® 40 mg/day for 120 days improved knee flexion, extension, and time to recovery from joint pain after strenuous exercise. Extends the indication beyond osteoarthritis to active adults wanting joint support.

Supported by Trial 3

Patented low-temperature processing

The patented manufacturing process preserves the triple-helix native collagen structure essential for the oral tolerance mechanism. Generic 'undenatured Type II collagen' preparations may use different processing methods that compromise native structure — destroying the immune-modulating activity entirely. Quality of processing is uniquely critical for this supplement class.

Standardization advantage

UC-II® provides reproducible ≥25% native Type II collagen content batch-to-batch. The standardization is what enables consistent clinical effects across trials and consumer products. Generic alternatives vary substantially in actual native Type II collagen content, even when labels claim similar amounts.

Supported by Trial 4, Trial 2

Trial-grade evidence consistency

Roughly 15+ years of clinical evidence using the same standardized UC-II® product. The consistency of the evidence base — same product, same dose, replicated results across populations — is unusual for natural supplement categories and supports confidence in the clinical claims.

Supported by Trial 2, Trial 1

Mechanism of action

1

Oral tolerance via gut-associated lymphoid tissue

UC-II® native Type II collagen interacts with M cells in Peyer's patches (gut-associated lymphoid tissue), where antigen-presenting cells process the collagen and induce regulatory T-cell tolerance. The result: regulatory T-cells circulate to joint tissue and suppress autoimmune attack on cartilage Type II collagen — the immunological mechanism distinguishing UC-II® from structural collagen supplementation.

2

Triple-helix structure preservation

The native triple-helix structure of Type II collagen is what GALT antigen-presenting cells recognize. Denatured (hydrolyzed) collagen loses this structure entirely — explaining why hydrolyzed collagen products at any dose can't replicate UC-II®'s mechanism. The patented low-temperature processing specifically preserves this structural requirement.

3

Cytokine modulation in joint tissue

Regulatory T-cells induced by UC-II® oral tolerance secrete anti-inflammatory cytokines (TGF-β, IL-10) in joint tissue, suppressing inflammatory cytokines (TNF-α, IL-1β, IL-6) that drive cartilage degradation in osteoarthritis. The mechanism produces sustained anti-inflammatory effects without systemic immune suppression.

4

Distinct from glucosamine and chondroitin substrate mechanism

Glucosamine and chondroitin work as substrates for cartilage matrix synthesis (building blocks). UC-II® works through immune modulation. The distinct mechanisms explain why UC-II® requires only 40 mg/day vs 2,700 mg/day for G+C, and why UC-II® may be effective when G+C isn't (different underlying biology being addressed).

Clinical trials

1
Foundational 2009 head-to-head trial

A 90-day RCT in 52 knee OA patients compared UC-II® 40 mg/day vs glucosamine 1,500 mg + chondroitin 1,200 mg. UC-II® reduced WOMAC scores 33% vs 14%; VAS pain 40% vs 15.4%. Foundational evidence establishing UC-II®'s superiority over the standard supplement comparator.

2
Multicenter 191-patient confirmation trial

A 180-day RCT in 191 knee OA patients across 13 centers in southern India confirmed UC-II® 40 mg/day significantly improved WOMAC scores vs both placebo and G+C. Replicated findings at larger sample size with longer follow-up.

3
Healthy active adults exercise study

A 120-day RCT in 55 healthy adults with exercise-induced knee pain showed UC-II® 40 mg/day improved knee flexion, extension, and pain recovery time after strenuous stepmill exertion. Extended indication beyond OA to athletic/active populations.

4
Long-term safety and tolerability

Across published trials, UC-II® 40 mg/day shows excellent tolerability with side effect rates comparable to placebo. No documented serious adverse events. Long-term safety data is more limited but reassuring for periods up to 180 days.

Side effects and drug interactions

Common Potential side effects

GENERALLY WELL-TOLERATED — side effects in clinical trials at rates comparable to placebo.
Avoid in individuals with chicken or egg allergies — chicken sternum source.
Mild GI discomfort possible in sensitive individuals; typically resolves with continued use.
No documented serious adverse events in published clinical trials.
Should be taken on empty stomach for optimal GALT presentation — food may interfere with mechanism.
Long-term safety data exists for periods up to 180 days; reassuring but limited compared to glucosamine.

Important Drug interactions

Generally minimal drug interactions documented.
No significant interactions with NSAIDs or other joint pain medications.
Theoretical caution with immunosuppressive medications — UC-II® modulates immune function, though direction (regulatory T-cell induction) suggests complementary rather than opposing effects.
No interactions with common cardiovascular, metabolic, or psychiatric medications.
Consult healthcare providers when combining with other supplements or medications for autoimmune conditions.

More Joint Health Ingredients

Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Bone Health
Copper
Copper is an essential trace mineral and cofactor for over 30 enzymatic reactions, includi…
Cardiovascular
Pycnogenol® (French Maritime Pine Bark)
Pycnogenol® (Horphag Research) is a standardized extract from the bark of French maritime…
Anti-Inflammatory
Meriva® (Curcumin Phytosome — Indena)
Meriva® is a CURCUMIN PHYTOSOME® formulation developed by Indena (Italy) — using Indena's…

Related articles from our blog

📝 Article
✨ Unlock the Power of Full‑Spectrum Collagen with CB Multi‑Collagen Protein
Collagen is the most abundant protein in your body, making up about 30% of total body protein and forming the structural…
June 17, 2025

Frequently asked questions about UC-II® (Undenatured Type II Collagen — Lonza)

What is UC-II® (Undenatured Type II Collagen — Lonza)?

UC-II® is the patented branded form of undenatured Type II collagen developed by InterHealth Nutraceuticals (now Lonza).

What does UC-II® (Undenatured Type II Collagen — Lonza) do?

UC-II® native Type II collagen interacts with M cells in Peyer's patches (gut-associated lymphoid tissue), where antigen-presenting cells process the collagen and induce regulatory T-cell tolerance. In clinical research, UC-II® (Undenatured Type II Collagen — Lonza) has been studied for knee osteoarthritis pain (patented evidence base), 2x better than glucosamine + chondroitin, multicenter validation trial.

Who should take UC-II® (Undenatured Type II Collagen — Lonza)?

UC-II® (Undenatured Type II Collagen — Lonza) may be most relevant for people interested in joint health. It has been clinically studied for knee osteoarthritis pain (patented evidence base), 2x better than glucosamine + chondroitin, multicenter validation trial. As with any supplement, consult your healthcare provider before starting, especially if you have medical conditions or take prescription medications.

How long does UC-II® (Undenatured Type II Collagen — Lonza) take to work?

Most clinical trial effects appear over weeks of consistent use; individual response varies. Acute or same-day effects (where applicable) typically appear within hours, but most cumulative benefits — particularly those affecting biomarkers, mood, sleep quality, or chronic symptoms — require 4-12 weeks of regular use to fully assess. If you don't notice benefit after 12 weeks at the appropriate dose, it may not be your responder.

When is the best time to take UC-II® (Undenatured Type II Collagen — Lonza)?

For anti-inflammatory and joint goals, UC-II® (Undenatured Type II Collagen — Lonza) is typically taken with meals — fat-containing food often improves absorption for fat-soluble compounds. Daily consistency matters more than precise timing for cumulative anti-inflammatory effects. Always check product labeling and follow personalized guidance from your healthcare provider.

Is UC-II® (Undenatured Type II Collagen — Lonza) worth taking?

UC-II® (Undenatured Type II Collagen — Lonza) has strong clinical evidence (Evidence Level 4/5 on NutraSmarts) for its primary uses, with multiple randomized controlled trials and meta-analyses supporting its benefits. Whether it's worth taking depends on your specific goals, what you've already tried, your budget, and your overall supplement strategy. The honest framing: no supplement is essential for most people, and lifestyle factors (sleep, exercise, diet, stress management) typically produce larger effects than any single supplement. UC-II® (Undenatured Type II Collagen — Lonza) is most worth trying if its evidence-supported uses align with your specific goals.

What is the recommended dosage of UC-II® (Undenatured Type II Collagen — Lonza)?

The clinically studied dose for UC-II® (Undenatured Type II Collagen — Lonza) is Clinical trial dose: 40 mg UC-II® once daily (providing ~10 mg native Type II collagen). Take on empty stomach (first thing in morning, 1 hour before food). Effects appear over 30-90 days. Avoid in chicken/egg allergies.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is UC-II® (Undenatured Type II Collagen — Lonza) used for?

UC-II® (Undenatured Type II Collagen — Lonza) is studied for knee osteoarthritis pain (patented evidence base), 2x better than glucosamine + chondroitin, multicenter validation trial. Multiple randomized trials using UC-II® specifically show 40 mg/day produces 30-40% WOMAC pain reduction in knee osteoarthritis over 90-180 days.